Cover Image

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE

Purpose: Somatostatin analogues (SSA) are frequently used in the treatment of neuroendocrine tumours. Recently, [18F]SiTATE entered the field of somatostatin receptor (SSR) positron emission tomography (PET)/computed tomography (CT) imaging. The purpose of this study was to compare the SSR-expressio...

Full description

Saved in:
Bibliographic Details
Main Authors: Eschbach, Ralf Stefan (Author) , Hofmann, Markus (Author) , Späth, Lukas (Author) , Sheikh, Gabriel T. (Author) , Delker, Astrid (Author) , Lindner, Simon (Author) , Jurkschat, Klaus (Author) , Wängler, Carmen (Author) , Wängler, Björn (Author) , Schirrmacher, Ralf (Author) , Tiling, Reinhold (Author) , Brendel, Matthias (Author) , Wenter, Vera (Author) , Dekorsy, Franziska J. (Author) , Zacherl, Mathias J. (Author) , Todica, Andrei (Author) , Ilhan, Harun (Author) , Grawe, Freba (Author) , Cyran, Clemens C. (Author) , Unterrainer, Marcus (Author) , Rübenthaler, Johannes (Author) , Knösel, Thomas (Author) , Paul, Tanja (Author) , Boeck, Stefan (Author) , Westphalen, Christoph Benedikt (Author) , Spitzweg, Christine (Author) , Auernhammer, Christoph J. (Author) , Bartenstein, Peter (Author) , Unterrainer, Lena M. (Author) , Beyer, Leonie (Author)
Format: Article (Journal)
Language:English
Published: 30 January 2023
In: Frontiers in oncology
Year: 2023, Volume: 13, Pages: 1-9
ISSN:2234-943X
DOI:10.3389/fonc.2023.992316
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fonc.2023.992316
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.992316/full
Get full text
Author Notes:Ralf S. Eschbach, Markus Hofmann, Lukas Späth, Gabriel T. Sheikh, Astrid Delker, Simon Lindner, Klaus Jurkschat, Carmen Wängler, Björn Wängler, Ralf Schirrmacher, Reinhold Tiling, Matthias Brendel, Vera Wenter, Franziska J. Dekorsy, Mathias J. Zacherl, Andrei Todica, Harun Ilhan, Freba Grawe, Clemens C. Cyran, Marcus Unterrainer, Johannes Rübenthaler, Thomas Knösel, Tanja Paul, Stefan Boeck, Christoph Benedikt Westphalen, Christine Spitzweg, Christoph J. Auernhammer, Peter Bartenstein, Lena M. Unterrainer and Leonie Beyer
Description
Summary:Purpose: Somatostatin analogues (SSA) are frequently used in the treatment of neuroendocrine tumours. Recently, [18F]SiTATE entered the field of somatostatin receptor (SSR) positron emission tomography (PET)/computed tomography (CT) imaging. The purpose of this study was to compare the SSR-expression of differentiated gastroentero-pancreatic neuroendocrine tumours (GEP-NET) measured by [18F]SiTATE-PET/CT in patients with and without previous treatment with long-acting SSAs to evaluate if SSA treatment needs to be paused prior to [18F]SiTATE-PET/CT. Methods: 77 patients were examined with standardised [18F]SiTATE-PET/CT within clinical routine: 40 patients with long-acting SSAs up to 28 days prior to PET/CT examination and 37 patients without pre-treatment with SSAs. Maximum and mean standardized uptake values (SUVmax and SUVmean) of tumours and metastases (liver, lymphnode, mesenteric/peritoneal and bones) as well as representative background tissues (liver, spleen, adrenal gland, blood pool, small intestine, lung, bone) were measured, SUV ratios (SUVR) were calculated between tumours/metastases and liver, likewise between tumours/metastases and corresponding specific background, and compared between the two groups. Results: SUVmean of liver (5.4 ± 1.5 vs. 6.8 ± 1.8) and spleen (17.5 ± 6.8 vs. 36.7 ± 10.3) were significantly lower (p < 0.001) and SUVmean of blood pool (1.7 ± 0.6 vs. 1.3 ± 0.3) was significantly higher (p < 0.001) in patients with SSA pre-treatment compared to patients without. No significant differences between tumour-to-liver and specific tumour-to-background SUVRs were observed between both groups (all p > 0.05). Conclusion: In patients previously treated with SSAs, a significantly lower SSR expression ([18F]SiTATE uptake) in normal liver and spleen tissue was observed, as previously reported for 68Ga-labelled SSAs, without significant reduction of tumour-to-background contrast. Therefore, there is no evidence that SSA treatment needs to be paused prior to [18F]SiTATE-PET/CT.
Item Description:Gesehen am 07.08.2024
Im Titel ist die Zahl 18 hochgestellt
Physical Description:Online Resource
ISSN:2234-943X
DOI:10.3389/fonc.2023.992316

Similar Items